Skip to main content
SpringerLink
Log in
Book cover

Combination Therapies 2 pp 171–177Cite as

Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes

  • Chapter

Abstract

Myelodisplastic syndrome (MDS) includes a spectrum of hematological alterations that have in common the progressive evolution of a monoclonal population of hemopoietic cells, arising from an initial genetic insult, to a preleukemic status and eventually to overt acute leukemia.1,2,3

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. K. Foucar, R.M. Langdom. J.O. Armitage, D.B. Olson, T.J. Carroll. Myelodisplastic syndromes, Cancer56: 553 (1985).

    Article  PubMed  CAS  Google Scholar 

  2. A. Jacobs, Human preleukemia: do we have a model ?. Br J Cancer55: 1 (1987).

    Article  PubMed  CAS  Google Scholar 

  3. D.G. Oscier, Myelodisplastic syndrome. Clin Haematol1: 389 (1987).

    CAS  Google Scholar 

  4. J.T. Prchal, D.W. Throckmorton, A.J. III Carrot, E.W. Fuson, R.A. Gams, J.F. Prchal. A common progenitor for human myeloid and lymphoid cells, Nature274: 590 (1978).

    Article  PubMed  CAS  Google Scholar 

  5. Y.W. Kan, New application for DNA polymorphism, V Engl JMed316: 478 (1987).

    Article  CAS  Google Scholar 

  6. R.A. Padua, G. Carter, D. Hughes, J. Gow, C. Farr, D. Oscier, F. McCormick, A. Jacobs, Ras mutation in myelodisplasia detected by amplification, oligonucleotide hybridization, and transformation, Leukemia2: 503 (1988).

    PubMed  CAS  Google Scholar 

  7. P.C. Nowell, E.C. Bes. T. Stelmach, J.B. Finan, Chromosome studies in preleukemic states: Prognostic significance of single vs. multiple abnormalities. Cancer58: 2571 (1986).

    Article  PubMed  CAS  Google Scholar 

  8. H. Van den Berghe, K. Vermaelen. C. Mecucci, D. Barbieri, G. Tricot. The 5q-anomaly, Cancer Genet Cytogenet17: 189 (1982).

    Article  Google Scholar 

  9. J.M. Bennett, D. Catovsky, G. Flandrin. D.A.G. Galton, H.R. Gralnick, C. Sultan, Proposals for the classification of the myelodisplastic syndromes, BRJ Haematol51: 189 (1982).

    CAS  Google Scholar 

  10. J.N. Winter, D. Variakojis, E.R. Gaynor, Low dose cytosine arabinoside therapy in the myelodisplastic yndromes and acute leukemia, Cancer56: 443 (1985).

    Article  PubMed  CAS  Google Scholar 

  11. J.D. Griffin, D. Spriggs, J. S. Wisch, Treatment of preleukemic syndromes with continuos intravenous infusion of low dose cytosine arabinoside, J Clin Oncol3: 982 (1985).

    PubMed  CAS  Google Scholar 

  12. G. Tricot, R. De Bock, A.W. Dekker. Low dose cytosine arabinoside in m,yelodisplastic syndromes, Br J Haematol58: 231 (1984).

    Article  PubMed  CAS  Google Scholar 

  13. L. Degos, S. Castaigne, H. Tilly. Treatment of leukemia with low dose ara-c: a study of 160 cases, Semin Oncol12 (supp1 3): 196 (1988).

    Google Scholar 

  14. J.D. Griffin, D. Munroe, P. Major, D. Kufe. Induction of differentiation of human myeloid leukemic cells by inhibitors of DNA synthesis, Exper Haematol10: 744 (1982).

    Google Scholar 

  15. L. Elias, R. Hoffman. S. Boswell. E. Bonnem, A trial of recombinant alpha-2 interferon in the myelodisplastic syndrome, Blood66(suppl) 675 (abstract) (1985).

    Google Scholar 

  16. F.R. Balkwill, R.T.D. Oliver, Growth inhibitory effects of interferon on normal and malignant human hemopoietic cells, Int J Cancer20: 500 (1977).

    Article  PubMed  CAS  Google Scholar 

  17. E.C. Borden, T.F. Hogan, J.G. Voelkel. Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells, Cancer Res42: 4948 (1982).

    PubMed  CAS  Google Scholar 

  18. K. C. Chadha, B.I. Srivastava, Comparison of the antiproliferative effects of human fibroblast and leukocyte interferons on various leukemic cell line,. J Clin Haematol Oncol11: 55 (1981).

    Google Scholar 

  19. J.S. Horoszewicz, S.S. Leong, W.S. Carter, Noncycling tumor cell are sensitive targets for the antiproliferative activity of human interferon, Science206: 1091 (1979).

    Article  PubMed  CAS  Google Scholar 

  20. A.A. Creasey, J.C. Bartholomew, T.C. Merigan, Role of GO-GI arrest in the inhibition of tumor cell growth by interferon, Proc:Vail icad Sci77: 1471 (1980).

    Article  CAS  Google Scholar 

  21. M. Gidlund, A. Orn, H. Wigzell, A. Senik, I. Gresser, Enhanced NK cell activity injected with interferon and interferon inducers, Nature273: 759 (1978).

    Article  PubMed  CAS  Google Scholar 

  22. R.B. Hebermann, H.T. Holden, Natural killer cells as antitumor effector cells. JNCJ62: 441 (1979).

    Google Scholar 

  23. J.Y. Djeu, J.A. Heinbaugh, H.T. Holden, R.B. Hebermann, Augmentation of mouse natural killer cell activity by interferon and interferon inducers, J Immunol122: 175 (1979).

    PubMed  CAS  Google Scholar 

  24. T. Timoten, J.R. Ortaldo, R.B. Hebermann. Characteristics of large granular lymphocytes and relationship to natural killer and killer cells. J Exp AIed153: 569 (1981).

    Article  Google Scholar 

  25. M.G. Masucci, R. Sziget, E. Klein. Effect of interferon alpha-1 from E.coli on some cell function, Science209: 1431 (1980).

    Article  PubMed  CAS  Google Scholar 

  26. J.R. Ortaldo, S. Pestka, R.B. Slease, M. Rubinstein, R.B. Hebermann, Augmentation of human k-cell activity with interferon, Scand Jlmmunol12: 365 (1980).

    Article  CAS  Google Scholar 

  27. P. Hokland, K. Berg, Interferon enhances the antibody-dependent cellular cytotoxicity of human polymorphonuclear leukocytes. J Innnunol127: 1585 (1981).

    CAS  Google Scholar 

  28. S. Sone, T. Utsugi, T. Shirhama. K. Ishii. S. Mutsuura. O. Mitsumasa. Induction by interferon-alpha of tumoricidal activity of adherent mononuclear cells from human blood: monocytes as responder and effector cells, J Biol Response Hod4: 134 (1985).

    CAS  Google Scholar 

  29. D. Fertsch, S.N. Vogel Recombinant interferons increase macrophage Fc receptor capacity, Jlmmunol132: 2436 (1984).

    CAS  Google Scholar 

  30. J.R. Sadlik, M. Hoyer, M.A. Leyko, Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon, Cancer45: 1940 (1985).

    CAS  Google Scholar 

  31. B. Harfast, J.R. Huddleston. P. Casali, T.C. Merigan. M.B.A. Oldstone, Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis, J Immunol127: 2146 (1981).

    PubMed  CAS  Google Scholar 

  32. M.A. Rodriguez, W.A. Prinz, W.L. Sibbitt. A.D. Bankhurst. R.C. Williams, Alpha-interferon increases immunoglobulin production in cultured human mononuclear leukocytes, Jbnmunol130: 1215 (1983).

    CAS  Google Scholar 

  33. I. Gresser, The effect of interferon on the expression of surface antigens, in“Interferons and the Immune System,” J. Vilcek. E. DeMaeyer. eds. Amsterdam (1984).

    Google Scholar 

  34. G. Sonnefeld, Effects of interferon on antibody formation, in“Interferons and the Immune System,” J. Vilcek, E. DeMaeyer, eds. Amsterdam (1984).

    Google Scholar 

  35. I. Heron, M. Hokland, K. Berg, Enhanced expression of B,-microglobulin and HLA antigens on human lymphoid cells by interferon, Proc Nail.1 cad Sci75: 6215 (1978).

    Article  CAS  Google Scholar 

  36. V.E. Kelley, W. Fiers, T.B. Strom. Cloned human interferon-gamma, but not interferon-beta or alpha induces expression og HLA-Dr determinants by fetal monocytes and myeloid leukemic cell lines, J Immunol132: 240 (1984).

    PubMed  CAS  Google Scholar 

  37. S.L. Lin, E.A. Garber, E. Wang,Reduced synthesis of pp60 and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells, Mol Cell Biol3: 1656 (1983).

    PubMed  CAS  Google Scholar 

  38. C.H. Dani, N. Mechti, M. Piechaczyk, B. Lebleu, P.H. Jeanteur, J.M. Blanchard, Increased rate of degradation of c-myc mRNA in interferon-treated Daudi cells, Proc Natl Acad Sci 82: 4891 (1985).

    Article  Google Scholar 

  39. D.R. Strayer, D.H. Gillespie, J. Bresseuer. J. Brodsky. Oncogene expression decreased in two patients treated with interferons, Blood 64(suppl):293(1984).

    Google Scholar 

  40. J. Pedersen-Bjengaard, S. Haahr. P. Philip. Abolished production of interferon by leucocytes of patients with the acquired cytogenetic abnormalities 5q-or -5 in secondary and de novo acute non lymphocytic leukemia, Br J Haematol46: 211 (1980).

    Article  Google Scholar 

  41. E. Garaci, F. Bistoni, C. Favalli, P. Marconi, V. Del Gobbo, C. Rainaldi, B.M. Jaffe, Thymic factors in experimental disease in“Immunoregulation,” W.A. Mithison eds, N. Fabris, E. Garaci, New York (1983).

    Google Scholar 

  42. A.S. Klein, R. Lang, I. Eshel, Y. Sharaby, J. Shoham, Modulation of immune response and tumor development in tumor-bearing mice treated by the factor thymostimulin, Cancer Res47: 3351 (1985).

    Google Scholar 

  43. M. Gidland, A. Orn, A. Wiezell. Enhanced NK cell activity in mice injected with interferon and interferons inducers, 273: 759 (1978).

    Google Scholar 

  44. E. Garaci, A. Mastino, T. Jezzi, C. Favalli. Thymic hormones and cytokines: a synergistic combination with high therapeutic potentialities in“Recent advances in autoimmunity and tumor immunology,” W.A. Mithison eds, E.Garaci, New York (1988).

    Google Scholar 

  45. C. Rinaldi-Garaci, M.R. Torrisi, T. Jezzi. L. Frati, A.L. Goldstein. E. Garaci, Receptors, for thimosin a on mouse thimocyte cells, Immunology91: 289 (1985).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cattedra di Ematologia - Ospedale S.Eugenio, Università di Roma “Tor Vergata”, Piazzale dell’ Umanesimo 10, 00144, Roma, Italy

    Adriano Venditti, Maria Teresa Scimo, Giovanni Del Poeta, Roberto Stasi, Ugo Coppetelli, Mario Masi, Manrico Cecconi, Maurizio Tribalto & Giuseppe Papa

  2. Cattedra di Microbiologia, Università di Roma “Tor Vergata”, Via Orazio Raimondo, 00174, Roma, Italy

    Cartesio Favalli & Enrico Garaci

Authors
  1. Adriano Venditti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Teresa Scimo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Del Poeta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberto Stasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ugo Coppetelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mario Masi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manrico Cecconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maurizio Tribalto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Giuseppe Papa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cartesio Favalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Enrico Garaci
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Rome “Tor Vergata”, Rome, Italy

    Enrico Garaci

  2. The Institute for Advanced Studies in Immunology and Aging, Washington, D.C., USA

    Allan L. Goldstein

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media New York

About this chapter

Cite this chapter

Venditti, A. et al. (1993). Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes. In: Garaci, E., Goldstein, A.L. (eds) Combination Therapies 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2964-4_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2964-4_20

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6289-0

  • Online ISBN: 978-1-4615-2964-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation